Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE IN ABSORBASE versus NASONEX 24HR ALLERGY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE IN ABSORBASE versus NASONEX 24HR ALLERGY.
HYDROCORTISONE IN ABSORBASE vs NASONEX 24HR ALLERGY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist that modulates gene expression, leading to anti-inflammatory, immunosuppressive, and vasoconstrictive effects.
Glucocorticoid receptor agonist; inhibits inflammatory mediators including cytokines, chemokines, and adhesion molecules; reduces nasal inflammation.
Topical: Apply a thin layer to affected area 2-4 times daily.
2 sprays (50 mcg/spray) per nostril once daily; total dose 200 mcg/day.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours (plasma cortisol); biological half-life (duration of action) 8-12 hours due to intracellular receptor effects.
The terminal elimination half-life of mometasone furoate is approximately 5.8 hours. This short half-life supports once-daily dosing for intranasal use, but systemic accumulation is minimal with topical administration.
Renal: primarily as 17-hydroxycorticosteroids and 17-ketosteroids; <5% unchanged. Biliary/fecal: minimal. Metabolites conjugated with glucuronide or sulfate.
Mometasone furoate is predominantly eliminated via biliary/fecal excretion. After intravenous administration, approximately 74% of the dose is recovered in feces and about 8% in urine. The drug undergoes extensive hepatic metabolism, and metabolites are excreted primarily in bile.
Category D/X
Category C
Corticosteroid
Corticosteroid, Intranasal